NCT03786484: Phase I/Ib Trial of Single Agent PBF-999 in Solid Tumour Advanced Cancer

NCT03786484
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic and/or untreated brain metastases
https://ClinicalTrials.gov/show/NCT03786484

Comments are closed.

Up ↑